| Literature DB >> 34046111 |
Miho Nishitani-Yokoyama1,2, Kazunori Shimada1,2, Miki Yamada2, Akio Honzawa2, Mitsuhiro Kunimoto1, Yurina Sugita1, Kei Fujiwara1, Tomomi Matsubara1, Rie Matsumori1, Abidan Abulimiti1, Akie Shimada3, Taira Yamamoto3, Tohru Asai3, Atsushi Amano3, Masakazu Saitoh4, Tomoyuki Morisawa4, Tetsuya Takahashi4, Hiroyuki Daida1,4, Tohru Minamino1.
Abstract
BACKGROUND: The Japanese Ministry of Health, Labour and Welfare reported that the overall constipation complaint rates among men and women are 2.5% and 4.6%, respectively. To evaluate the impact of constipation on patients with cardiovascular diseases, we investigated the association between constipation and frailty components in patients undergoing cardiac rehabilitation (CR).Entities:
Keywords: Cardiac rehabilitation; Cardiovascular disease; Constipation; Defecation; Frailty
Year: 2021 PMID: 34046111 PMCID: PMC8139749 DOI: 10.14740/cr1246
Source DB: PubMed Journal: Cardiol Res ISSN: 1923-2829
Figure 1The number of applicable items for functional constipation diagnosis criteria. Subjects were classified into constipation (n = 33, 32%) and non-constipation (n = 69, 68%) groups according to the Chronic Constipation Treatment Guidelines.
Figure 2Comparison of constipation prevalence and complaint rates in patients undergoing late phase II cardiac rehabilitation.
Clinical Characteristics of the Study Subjects
| All subjects (n = 102) | Constipation group (n = 33) | Non-constipation group (n = 69) | P value | |
|---|---|---|---|---|
| Age, years | 62.7 ± 13.4 | 71.5 ± 11.2 | 58.5 ± 12.4 | < 0.01 |
| Male, n (%) | 68 (67) | 20 (61) | 48 (70) | 0.37 |
| Body mass index, kg/m2 | 24.0 ± 4.4 | 22.8 ± 3.3 | 24.5 ± 4.7 | 0.03 |
| Hypertension, n (%) | 59 (58) | 17 (51) | 42 (61) | 0.37 |
| Diabetes mellitus, n (%) | 12 (12) | 3 (9) | 10 (14) | 0.44 |
| Dyslipidemia, n (%) | 30 (29) | 12 (36) | 18 (26) | 0.28 |
| Current smoking, n (%) | 10 (18) | 1 (6) | 9 (23) | 0.27 |
| CVD at the beginning of CR, n (%) | ||||
| Chronic heart failure | 64 (63) | 22 (67) | 43 (62) | 0.52 |
| Aortic disease | 22 (21) | 8 (24) | 14 (20) | |
| Acute myocardial infarction | 16 (16) | 3 (9) | 12 (18) | |
| Atrial fibrillation | 25 (25) | 11 (33) | 14 (20) | 0.15 |
| Laboratory data | ||||
| Hemoglobin, g/dL | 13.1 ± 2.0 | 12.3 ± 1.8 | 13.4 ± 2.0 | < 0.01 |
| Albumin, g/dL | 3.8 ± 0.4 | 3.6 ± 0.4 | 3.9 ± 0.4 | < 0.01 |
| Creatinine, mg/dL | 1.07 ± 0.56 | 1.23 ± 0.67 | 0.99 ± 0.49 | 0.04 |
| eGFR, mL/min/1.73 m2 | 59.4 ± 20.6 | 50.7 ± 20.2 | 63.8 ± 19.3 | < 0.01 |
| Total cholesterol, mg/dL | 174 ± 32 | 170 ± 33 | 175 ± 33 | 0.55 |
| Triglyceride, mg/dL | 118 ± 97 | 115 ± 65 | 120 ± 110 | 0.82 |
| HDL-C, mg/dL | 50 ± 12 | 50 ± 13 | 50 ± 12 | 0.96 |
| LDL-C, mg/dL | 99 ± 30 | 92 ± 27 | 104 ± 30 | 0.07 |
| FBS, mg/dL | 104 ± 27 | 98 ± 18 | 106 ± 30 | 0.15 |
| Hemoglobin A1c, % | 5.9 ± 0.7 | 5.8 ± 0.4 | 5.9 ± 0.8 | 0.85 |
| BNP, pg/mL | 290 ± 348 | 361 ± 478 | 242 ± 221 | 0.20 |
| NT-proBNP, pg/mL | 1,855 ± 3,122 | 3,069 ± 2,989 | 1,855 ± 3,122 | 0.23 |
| GNRI | 100.1 ± 12.3 | 97.1 ± 10.7 | 103.3 ± 12.8 | 0.03 |
| Ejection fraction, % | 51.0 ± 17.5 | 51.6 ± 18.1 | 50.8 ± 17.4 | 0.81 |
| Medications, n (%) | ||||
| ACE-I | 33 (32) | 10 (30) | 23 (33) | 0.75 |
| ARB | 37 (36) | 12 (36) | 25 (36) | 0.98 |
| β-blockers | 87 (85) | 28 (85) | 59 (85) | 0.93 |
| CCB | 28 (27) | 6 (18) | 22 (32) | 0.14 |
| Loop diuretic | 66 (64) | 23 (70) | 43 (62) | 0.46 |
| Vasopressin antagonist | 16 (16) | 7 (21) | 9 (13) | 0.46 |
| Potassium-sparing diuretic | 39 (38) | 11 (33) | 28 (41) | 0.48 |
| Statin | 39 (38) | 14 (42) | 25 (36) | 0.54 |
| OHA | 8 (8) | 2 (6) | 6 (9) | 0.64 |
| Insulin | 2 (2) | 1 (3) | 1 (1) | 0.59 |
| Sleeping pills | 8 (8) | 3 (9) | 5 (7) | 0.74 |
| Proton pump inhibitor | 69 (67) | 22 (67) | 47 (68) | 0.88 |
| Laxatives | 31 (30) | 16 (48) | 15 (22) | < 0.01 |
| Irritant laxative | 18 (18) | 11 (34) | 7 (10) | < 0.01 |
| Lubiprostone | 4 (4) | 4 (12) | 0 (0) | < 0.01 |
| Osmotic laxative | 19 (19) | 7 (21) | 12 (17) | 0.20 |
| Herbal medicine | 5 (5) | 2 (6) | 3 (4) | 0.74 |
Data are presented as the mean ± SD. CVD: cardiovascular disease; CR: cardiac rehabilitation; eGFR: estimated glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FBS: fasting blood sugar; BNP: brain natriuretic peptide; NT-proBNP: N-terminal pro brain natriuretic peptide; GNRI: Geriatric Nutritional Risk Index; ACE-I: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CCB: calcium-channel blocker; OHA: oral hypoglycemic agent.
Comparison of Frailty Components Between the Constipation and Non-Constipation Groups
| All subjects (n = 102) | Constipation group (n = 33) | Non-constipation group (n = 69) | P value | |
|---|---|---|---|---|
| Kihon checklist score | ||||
| Activities of daily living | 0.80 ± 1.16 | 1.09 ± 1.55 | 0.68 ± 0.91 | 0.09 |
| Physical function | 1.21 ± 1.26 | 1.60 ± 1.24 | 1.04 ± 1.22 | 0.03 |
| Nutritional status | 0.60 ± 0.60 | 1.09 ± 0.94 | 0.71 ± 0.94 | 0.05 |
| Oral function | 0.82 ± 0.95 | 0.63 ± 0.60 | 0.61 ± 0.62 | 0.83 |
| Social activities of daily living | 0.40 ± 0.56 | 0.58 ± 0.56 | 0.31 ± 0.55 | 0.03 |
| Cognitive function | 0.35 ± 0.60 | 0.48 ± 0.66 | 0.30 ± 0.57 | 0.16 |
| Depressive mood | 1.89 ± 1.74 | 2.67 ± 1.57 | 1.53 ± 1.70 | < 0.01 |
| Total score | 6.02 ± 4.20 | 8.15 ± 4.24 | 5.20 ± 3.87 | < 0.01 |
| Prevalence of frailty | ||||
| Frailty, n (%) | 35 (34) | 18 (55) | 17 (25) | 0.01 |
| Pre-frailty, n (%) | 35 (34) | 10 (30) | 25 (36) | |
| Non-frailty, n (%) | 32 (32) | 5 (15) | 27 (39) |
Data are presented as the mean ± SD.
Figure 3Comparison of diagnostic criteria for functional constipation between the constipation and non-constipation groups.
Figure 4Comparison of Bristol Stool Form Scale between the constipation and non-constipation groups.